Teva Settles with Patent Litigation with Perrigo, CatalentBy
This settlement dismisses pending litigation in the
There are currently no additional challenges to the IP for ProAir HFA and no further litigation pending. Teva said it will continue to vigorously defend its intellectual property rights relating to its products.
ProAir HFA is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Source: Teva Pharmaceuticals Industries and Perrigo